Teva/Active Biotech Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva and Active Biotech's proposed collaboration on the development and commercialization of laquinimod has been cleared by the Federal Trade Commission, the companies announced Aug. 24
You may also be interested in...
Teva/Active Biotech Initiate Phase III Program For Laquinimod Oral MS Therapy
Firm enters Phase III along with Acorda, Biogen Idec, others in race to bring first oral MS agent to market.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.